Abstract
The Act for the Comprehensive Acceleration of Policies Promptly to Give the People Regenerative Medicine Free from Danger (Act for the Promotion of Regenerative Medicine) was enacted in April and enforced in May 2013, and the enforcement of the Act led to the Act Concerning Safety Assurance of Regenerative Medicine (Act on the Safety of Regenerative Medicine) and the Revised Pharmaceutical Affairs Law (Pharmaceuticals and Medical Devices Law) (enacted in November 2013 and enforced on November 25, 2014). The old Pharmaceutical Affairs Law had only two categories, pharmaceuticals and medical devices, and therefore was an obstacle to the development of regenerative medicinal products under pharmaceutical regulations. It was a great trouble for us in academe, and we had to treat patients in uneasy darkness without the landmarks and lights of regulations. The solutions for the problem are an upgrade to the Guidelines for Clinical Research Using Human Stem Cells to the Act on the Safety of Regenerative Medicine and the introduction of a new category, cellular- and tissue-based products, under the Revised Pharmaceutical Affairs Law or Pharmaceuticals and Medical Devices Law. We have obtained two paths for generalization of regenerative medicine in our society. Among the so-called advanced nations, only Japan has these two paths, and the whole world is watching carefully the start of the grand social experiment for the release of regenerative medicine into society. The selected path would be the answer from the general public to the question of how to establish regenerative medicine in society.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Act for the Comprehensive Acceleration of Policies Promptly to Give the People Regenerative Medicine Free from Danger law. http://law.e-gov.go.jp/htmldata/H25/H25HO013.html
Act Concerning Safety Assurance of Regenerative Medicine law. http://law.e-gov.go.jp/announce/H25HO085.html
Pharmaceuticals and Medical Devices Law http://law.e-gov.go.jp/htmldata/S35/S35HO145.html
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Japan
About this chapter
Cite this chapter
Okura, H., Matsuyama, A. (2016). Critical Path Initiative for Regenerative Medicine in Japan. In: Terai, S., Suda, T. (eds) Gene Therapy and Cell Therapy Through the Liver. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55666-4_12
Download citation
DOI: https://doi.org/10.1007/978-4-431-55666-4_12
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55665-7
Online ISBN: 978-4-431-55666-4
eBook Packages: MedicineMedicine (R0)